# EDGAR Filing Document

**Accession Number:** 0001600301
**File Stem:** 0001823239-25-000093
**Filing Date:** 2025-6
**Character Count:** 7698
**Document Hash:** 6c4f669a9272cce0d0f01f6e03016f83
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001823239-25-000093.hdr.sgml**: 20250630

**ACCESSION NUMBER**: 0001823239-25-000093

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250630

**DATE AS OF CHANGE**: 20250630

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Asarpota Rajesh
- **CENTRAL INDEX KEY:** 0001600301

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39725
- **FILM NUMBER:** 251093572

**MAIL ADDRESS:**
- **STREET 1:** 1300 N. KELLOGG DRIVE SUITE D
- **CITY:** ANAHEIM
- **STATE:** CA
- **ZIP:** 92807
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MARAVAI LIFESCIENCES HOLDINGS, INC.
- **CENTRAL INDEX KEY:** 0001823239
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 10770 WATERIDGE CIRCLE SUITE 200
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** (858) 546-0004

**MAIL ADDRESS:**
- **STREET 1:** 10770 WATERIDGE CIRCLE SUITE 200
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Asarpota Rajesh<br><sub>(Last) (First) (Middle)</sub><br>C/O MARAVAI LIFESCIENCES HOLDINGS, INC.<br>10770 WATERIDGE CIRCLE, SUITE 200<br><sub>(Street)</sub><br>SAN DIEGO, CA 92121<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-06-30 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Financial Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>MARAVAI LIFESCIENCES HOLDINGS, INC. [ MRVI ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Class A Common Stock | 2025-06-30 |  | A |  | 500000 | A | <sup>(1)</sup> | 500000 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Employee Stock Option (Right to Buy) | $2.41 | 2025-06-30 |  | A |  | 333333 |  | <sup>(2)</sup> | 2035-06-30 | Class A Common Stock | 333333 | $0 | 333333 | D |  |
| Performance Stock Units | <sup>(3)</sup> | 2025-06-30 |  | A |  | 750000 |  | <sup>(3)</sup> | 2028-07-30 | Class A Common Stock | 750000 | $0 | 750000 | D |  |

---

### Footnotes:

(1) Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan (the "Omnibus Incentive Plan"). Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting. The RSUs vest over a three-year period, with one-third of the RSUs vesting on the first anniversary of the grant date and the remaining two-thirds of the RSUs vesting in 24 substantially equal monthly installments, subject to the Reporting Person's continued employment with the Issuer (except as otherwise provided in connection with certain circumstances as set forth in the award agreement).

(2) Represents options awarded under the Omnibus Incentive Plan. These options vest over a three-year period, with one-third of the options vesting on the first anniversary of the grant date and the remaining two-thirds of the options vesting in 24 substantially equal monthly installments, subject to the Reporting Person's continued employment with the Issuer (except as otherwise provided in connection with certain circumstances as set forth in the award agreement).

(3) Represents performance-based restricted stock units ("PSUs") awarded under the Omnibus Incentive Plan. Each PSU represents the contingent right to receive one share of Class A Common Stock of the Issuer. The PSUs will vest if and to the extent the volume-weighted average price of a share of the Class A Common Stock of the Issuer equals or exceeds certain thresholds for the 30 consecutive trading days immediately preceding the third anniversary of the grant date, subject to the Reporting Person's continued employment with the Issuer (except as otherwise provided in connection with certain circumstances as set forth in the award agreement).

**Signature:** /s/ Kurt Oreshack, by power of attorney for Rajesh Asarpota  
**Date:** 2025-06-30

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**